首页> 外文期刊>Clinical & translational oncology : >Clinical and mutation analysis of four Chinese families with von Hippel-Lindau disease.
【24h】

Clinical and mutation analysis of four Chinese families with von Hippel-Lindau disease.

机译:四个中国人患有von Hippel-Lindau病的临床和突变分析。

获取原文
获取原文并翻译 | 示例
           

摘要

von Hippel-Lindau (VHL) disease is a hereditary tumor syndrome predisposed to the development of tumors in a variety of body organs. The major etiopathogenesis of VHL is a mutation of the VHL tumor-suppressor gene on the short arm of chromosome 3 (3p25-26). We report on the clinical and molecular features of four Chinese kindreds with VHL disease.The VHL gene was screened for mutation using a direct DNA sequencing analysis and a multiplex ligation-dependent probe amplification (MLPA) for 44 volunteers from these four families. Any unaffected person, with germline VHL gene mutation, was required to undergo further examination, surveillance and treatment.The main lesions and the average diagnostic year of the 20 patients were central nervous system hemangioblastoma (60 %, 34.92 years), renal lesion (60 %, 39.08 years), pancreatic lesion (60 %, 37.67 years), adrenal pheochromocytoma (25 %, 37.8 years) and retinal hemangioblastoma (10 %, 25.5 years). Direct sequencing detected nucleotide substitutions or small deletions in three families and MLPA revealed exon 1 deletion in family A. The five asymptomatic patients were initially diagnosed by genetic analysis and verified radiologically or surgically.The spectrum of clinical manifestation of VHL in the mainland Chinese population is similar to the observation in Western kindreds. Genetic testing, which plays a crucial role in early diagnosis asymptomatic patients, is obviously superior to clinical informations when diagnosing VHL disease. The members of VHL disease family may benefit from pedigree study, genetic testing, periodic follow-up, early diagnosis and prompt treatment.
机译:von Hippel-Lindau(VHL)病是一种遗传性肿瘤综合征,易患各种身体器官中的肿瘤。 VHL的主要病因是在3号染色体(3p25-26)短臂上的VHL肿瘤抑制基因的突变。我们报道了四名中国VHL家族的临床和分子特征。使用直接DNA测序分析和多重连接依赖探针扩增(MLPA)方法对这四个家族的44名志愿者进行了VHL基因突变筛选。任何患有生殖系VHL基因突变的未受影响的人都需要接受进一步检查,监测和治疗.20例患者的主要病变和平均诊断年为中枢神经系统血管母细胞瘤(60%,34.92岁),肾病变(60 %,39.08岁),胰腺病变(60%,37.67岁),肾上腺嗜铬细胞瘤(25%,37.8岁)和视网膜血管母细胞瘤(10%,25.5岁)。直接测序法检测到三个家族中的核苷酸取代或微小缺失,而MLPA显示A家族中第1外显子缺失。这5例无症状患者最初通过基因分析被诊断并通过放射学或外科手术证实.VHL在中国大陆人群中的临床表现谱为类似于西方亲戚的观察。基因诊断在无症状患者的早期诊断中起着至关重要的作用,在诊断VHL疾病时明显优于临床信息。 VHL疾病家族的成员可能会受益于谱系研究,基因检测,定期随访,早期诊断和及时治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号